Rational design of RAR-selective ligands revealed by RARbeta crystal stucture.

Area of Science:

• Molecular Biology
• Structural Biology
• Pharmacology

Background:

• Retinoic acid receptors (RARs) are crucial nuclear receptors involved in gene regulation.
• RARbeta is implicated as a tumor suppressor, but its selective targeting remains challenging.
• Understanding structural differences between RAR isotypes is key for developing selective modulators.

Purpose of the Study:

• To elucidate the structural basis for RARbeta selectivity.
• To identify RARbeta-selective agonists and antagonists.
• To provide guidelines for synthesizing novel RARbeta-targeting drugs.

Main Methods:

• X-ray crystallography to determine the ligand-binding domain structure of RARbeta.
• Biochemical assays to measure ligand binding affinities to RAR isotypes.
• Structure-based drug design principles to guide ligand modification.

Main Results:

• RARbeta possesses an additional cavity compared to RARalpha and RARgamma, accommodating bulkier agonists.
• A novel ligand was identified with 100-fold higher affinity for RARbeta over RARalpha/gamma.
• Structural insights explain retinoid dual activity (antagonist for RARalpha/gamma, agonist for RARbeta).
• A strategy to generate RARbeta antagonists by modifying ligand bulkiness was demonstrated.

Conclusions:

• Structural variations in RAR ligand-binding pockets dictate isotype selectivity.
• Targeted synthesis of RARbeta-selective agonists and antagonists is feasible.
• These findings enable pharmacological investigation of RARbeta's tumor suppressor functions.